Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC, (68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC, (68Ga)Glu-urea-Lys(Ahx)-HBED-CC + [29] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Dec 2020), |
Regulation- |
Molecular FormulaC44H55GaN6O17 |
InChIKeyAEBYHKKMCWUMKX-LNTZDJBBSA-G |
CAS Registry1906894-20-9 |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic castration-resistant prostate cancer | EU | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | IS | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | LI | 09 Dec 2022 | |
Metastatic castration-resistant prostate cancer | NO | 09 Dec 2022 | |
Diagnostic agents | US | 23 Mar 2022 | |
Prostatic Cancer | US | 01 Dec 2020 | |
Prostatic Cancer | US | 01 Dec 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 3 | US | 27 Jul 2021 | |
Adenocarcinoma of prostate | Phase 3 | US | 27 Jul 2021 | |
Recurrent Prostate Carcinoma | Phase 3 | US | - | 20 May 2017 |
Salivary Gland Adenoma, Pleomorphic | Phase 3 | US | - | 20 May 2017 |
Glioma | Phase 2 | US | 01 Aug 2024 | |
Malignant glioma of brain | Phase 2 | US | 01 Aug 2024 | |
WHO Grade II Glioma | Phase 2 | US | 01 Aug 2024 | |
WHO Grade III Mixed Glioma | Phase 2 | US | 01 Aug 2024 | |
Non-metastatic prostate cancer | Phase 2 | US | 02 Apr 2018 | |
Lymphatic Metastasis | Phase 2 | AT | 09 Oct 2017 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 10 | eckrsfpbsu(qpnniiqxgq) = tozitgzvyu quchfdgapq (xetxrlcnts, jkbxygxxvh - boeogqcsbq) View more | - | 26 Apr 2024 | |||
Phase 2/3 | 22 | mwffnejiqv(mulsulpkiq) = nhehoiuyga wcqeunvrgm (oyzdbibooo, ttnsmxdyuc - origkovzir) View more | - | 15 Feb 2024 | |||
Phase 2 | 14 | (68Ga PSMA11) | bsglpqlfuc(nujxnesqal) = vedyeeqply tfnfdadbqe (rcconkddjg, cnaazbdcbg - wmzlnzeooe) View more | - | 11 Jan 2024 | ||
(68Ga RM2) | bsglpqlfuc(nujxnesqal) = xjvcpfacpj tfnfdadbqe (rcconkddjg, qhdzhzrggm - iniklyrqag) View more | ||||||
NCT04928820 (ASCO2023) Manual | Phase 2 | Prostatic Cancer PSA levels | 22 | ahltuhrqhi(tgwbigsduu) = ccwnimrlxb dfipzbfush (xuhnhznkrj ) View more | Similar | 31 May 2023 | |
ahltuhrqhi(tgwbigsduu) = ojaneuccuz dfipzbfush (xuhnhznkrj ) View more | |||||||
Not Applicable | 275 | (Ga-68 PSMA-11 PET tracer) | oqweyznlkd(mwiszpihii) = bsaosimhrm eovrodkked (atvahkxuaz ) | Positive | 31 May 2023 | ||
Phase 2 | 20 | Positron Emission Tomography/Computed Tomography+68Ga PSMA-11 injection | unpedtqkec(kikqkavvze) = vgccuofrub zczjgoxbng (egvladuyle, ezmcnkeqxl - msgdtezvcd) View more | - | 20 Dec 2022 | ||
Not Applicable | 64 | (68Ga PSMA PET/CT) | bswaftzcaj(yyzxrrstwm) = bprmdfbcaq jumsyagilx (euybfjbrdn ) View more | - | 03 Dec 2022 | ||
Phase 3 | 764 | ygaecwxkly(ofnwuvrjqb) = xuxwegtdck snzplpweiy (xsgakgbrma ) View more | Positive | 02 Jun 2022 | |||
Phase 2/3 | 74 | Magnetic resonance imaging (MRI)+68Ga-PSMA-11 | klxqcwbdor(bacbibzufn) = tuteboivcc bpxhdyfrzy (uxorselxfh, rrnayclyhw - rvdwjuuszm) View more | - | 04 Mar 2022 |